Lack of antilipoprotein lipase antibodies in takayasu's arteritis

Jozélio Freire De Carvalho, Rosa Maria Rodrigues Pereira, Vilma Santos Trindade Viana, Eloísa Bonfá, Yehuda Shoenfeld

Research output: Contribution to journalArticlepeer-review


Background. Antilipoprotein lipase (anti-LPL) antibodies were described in rheumatic diseases. In systemic lupus erythematosus they were highly associated with inflammatory markers and dyslipidemia, and may ultimately contribute to vascular damage. The relevance of this association in Takayasu's arteritis, which is characterized by major inflammatory process affecting vessels, has not been determined. Objectives. To analyze the presence of anti-LPL antibodies in patients with Takayasu's arteritis and its association with inflammatory markers and lipoprotein risk levels. Methods. Thirty sera from patients with Takayasu's arteritis, according to ACR criteria, were consecutively included. IgG anti-LPL was detected by a standard ELISA. Lipoprotein risk levels were evaluated according to NCEP/ATPIII. Inflammatory markers included ESR and CRP values. Results. Takayasu's arteritis patients had a mean age of 34 years old and all were females. Half of the patients presented high ESR and 60 elevated CRP. Lipoprotein NCEP risk levels were observed in approximately half of the patients: 53 for total cholesterol, 43 for triglycerides, 16 for HDL-c and 47 for LDL-c. In spite of the high frequency of dyslipidemia and inflammatory markers in these patients no anti-LPL were detected. Conclusions. The lack of anti-LPL antibodies in Takayasu's disease implies distinct mechanisms underlying dyslipidemia compared to systemic lupus erythematosus.

Original languageEnglish
Article number803409
JournalClinical and Developmental Immunology
StatePublished - 2009
Externally publishedYes


Dive into the research topics of 'Lack of antilipoprotein lipase antibodies in takayasu's arteritis'. Together they form a unique fingerprint.

Cite this